Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring
Open accessThe DOI matches its Crossref record; 228 of the 232 references it cites were found in a registry or an index.
Abstract
Background. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting many individuals worldwide with no effective treatment to date. AD is characterized by the formation of senile plaques and neurofibrillary tangles, followed by neurodegeneration, which leads to cognitive decline and eventually death. Introduction. In AD, pathological changes occur many years before disease onset. Since disease-modifying therapies may be the most beneficial in the early stages of AD, biomarkers for the early diagnosis and longitudinal monitoring of disease progression are essential. Multiple imaging techniques with associated biomarkers are used to identify and monitor AD. Aim. In this review, we discuss the contemporary early diagnosis and longitudinal monitoring of AD with imaging techniques regarding their diagnostic utility, benefits and limitations. Additionally, novel techniques, applications and biomarkers for AD research are assessed. Findings. Reduced hippocampal volume is a biomarker for neurodegeneration, but atrophy is not an AD-specific measure. Hypometabolism in temporoparietal regions is seen as a biomarker for AD. However, glucose uptake reflects astrocyte function rather than neuronal function. Amyloid-β (Aβ) is the earliest hallmark of AD and can be measured with positron emission tomography (PET), but Aβ accumulation stagnates as disease progresses. Therefore, Aβ may not be a suitable biomarker for monitoring disease progression. The measurement of tau accumulation with PET radiotracers exhibited promising results in both early diagnosis and longitudinal monitoring, but large-scale validation of these radiotracers is required. The implementation of new processing techniques, applications of other imaging techniques and novel biomarkers can contribute to understanding AD and finding a cure. Conclusions. Several biomarkers are proposed for the early diagnosis and longitudinal monitoring of AD with imaging techniques, but all these biomarkers have their limitations regarding specificity, reliability and sensitivity. Future perspectives. Future research should focus on expanding the employment of imaging techniques and identifying novel biomarkers that reflect AD pathology in the earliest stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The Alzheimer’s disease continuum with corresponding pathological changes, biomarkers and clinical diagnosis. Figure adapted from Yoshiyama et al. [21].](https://figures.cochat.ai/paper-figures/5ed93dc48917473ca30ad0e7a8a74987/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-1.jpg)
![Figure 6 Tau spreading pattern in each Braak stage. Spreading pattern of tau throughout the brain from Braak stage I-II to stage III-IV (limbic regions) and stage V-VI (isocortical areas). Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/f800c1b6e6e24d13ba3b3f4e8509a14d/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-6.jpg)


![Figure 4 Accumulation of amyloid-β in AD. Figure adapted from Patterson et al. [89] and created with www.BioRender.com (accessed on 16 November 2020).](https://figures.cochat.ai/paper-figures/49d3fbddca5e428ea039b5bd152e68a0/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-4.jpg)


![Figure 8 Spreading pattern of amyloid-β accumulation throughout the brain. Amyloid-β accumulation starts in frontal areas and spreads to other regions as disease progresses, leading to a plateau in amyloid-β as disease progresses. Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/d4b1f0c188954fbdb7a6946c934ad246/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, sMRI and (18FDG)-PET indicate neurodegeneration or neuronal injury in the AT(N) framework with limitations in specifically diagnosing AD.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They cannot accurately differentiate AD from other neurodegenerative diseases with similar pathologies, such as frontotemporal degeneration and TDP-43 proteinopathies with medial temporal lobe atrophy.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD diagnosis relies on detecting amyloid and tau pathology via positron emission tomography (PET), magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) analysis [8,9,10].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“, reporting decreased metabolism in the same two medial prefrontal regions [3,157] Altogether, these findings highlight the potential of FDG-PET for the longitudinal monitoring of AD progression.”
BackgroundInfluentialThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Huang, D., Swanson, E. A., Lin, C. P., Schuman, J. S., Stinson, W. G., Chang, W., Hee, M. R., Flotte, T., Gregory, K., Puliafito, C. A., et al. (1991) · Science · doi:10.1126/science.1957169 · Cited by 13,788
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Voxel-Based Morphometry—The Methods
Ashburner, J., & Friston, K. J. (2000) · NeuroImage · doi:10.1006/nimg.2000.0582 · Cited by 8,676 · cited 7×
“Currently, two distinct biomarkers are used to assess Aβ pathology: the concentration of Aβ42 in the CSF and 2.3.2.”
MethodInfluentialAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 2×
“leading to the formation of senile plaques [7,20,82,83].”
BackgroundFunctional connectivity in the resting brain: a network analysis of the default mode hypothesis
Greicius, M. D., Krasnow, B., Reiss, A. L., & Menon, V. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0135058100 · Cited by 6,358
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“All other disease characteristics, such as the formation of NFTs out of hyperphosphorylated tau, and neurodegeneration, are seen a result of this accumulation [12,83,88].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 2×
“This statement is further underlined by the hypothetical model of dynamic biomarkers [77,78].”
BackgroundQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Cited by
Items 201–300 of 351
An, X., Wang, Y., Cao, M., Yi, Z., Zeng, X., Yu, W., & Ren, Z. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261423079 · Cited by 1
“4,5 8 They often lead to diagnoses only in the later stages of the disease.”
Dementia Appraisal: Overview of Good Clinical Practices, Barriers, and Gaps for Integrated Care
Margarida, A., Meira, B., Raquel, B., Francisco, P. M. B., Henrique, L., & Maria, V. A. (2023) · International Journal of Geriatrics and Gerontology · doi:10.29011/2577-0748.100073 · Cited by 1
In vivo two-photon FLIM imaging to investigate metabolism in live animals
Sagar, V. K., Norambuena, A., Wallrabe, H. K., Alam, S. R., Pardo, E., & Periasamy, A. (2024) · Multiphoton Microscopy in the Biomedical Sciences · doi:10.1117/12.3003082 · Cited by 1
“…and the current clinical imaging modalities of AD pathology include magnetic resonance imaging (MRI), functional MRI (fMRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT) along with computed tomography (CT) and magnetic resonance spectroscopy (MRS) [7], [8].”
BackgroundUpcoming Nano and Conventional Drug Delivery Strategies for Alzheimer’s Disease
Varghese, N. M., Sathyamoorthy, N., Krishnamurthy, P. T., Varshini, M. S., & Chintamaneni, P. K. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_16 · Cited by 1
APOE Polymorphism and Brain Imaging
Obenaus, A., & Territo, P. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_69-1 · Cited by 1
Chen, X., Chen, L., Yao, W., Zuo, Q., Li, Y., Liang, D., Wang, S., Wang, M., & Sun, T. (2025) · NeuroImage · doi:10.1016/j.neuroimage.2025.121510 · Cited by 1
Chinnathambi, S., Rangappa, N., Velmurugan, G., & Chandrashekar, M. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.018 · Cited by 1
Predictive modeling approaches for Alzheimer's disease diagnosis through neuroimaging techniques
Pandey, K. K., Mishra, A., & Milan, R. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102989 · Cited by 1
Alzheimer’s Disease Detection Using Lightweight Convolutional Neural Network on MRI Scans
Niyonkuru, V., Sylla, S., Kasuli, Z. A., Sinzinkayo, J. J., & Kabanga, D. (2025) · American Journal of Bioscience and Bioinformatics · doi:10.54536/ajbb.v4i1.5943 · Cited by 1
“MRI scanning provides a non-invasive technique for detecting alterations in the brain as observed in AD (Murguiondo-Pérez et al ., 2025; Kaštelan et al ., 2025; van Oostveen et al ., 2021).”
MCR-VQGAN: A Scalable and Cost-Effective Tau PET Synthesis Approach for Alzheimer’s Disease Imaging
Kim, J. Y., Hudson, J., Kim, J., Lyu, Q., & Whitlow, C. T. (2026) · IEEE Access · doi:10.1109/access.2026.3703426 · Cited by 1
“Consequently, tau positron emission tomography (PET) has become a key imaging modality, enabling direct visualization and quantification of tau deposits [6], [7].”
TLRs and NLRs modulate oral microbiome involvement in Alzheimer’s disease
Motevalli, H., Mehrani, A., Zolfaghari, K., Khodaee, P., Yazdanpanah, N., Saleki, K., & Rezaei, N. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01771-y · Cited by 1
“Imaging techniques, including MRI, SPECT, tau PET, amyloid PET, and FDG-PET, also have a special place in the early diagnosis and follow-up of AD (van Oostveen And de Lange 2021; O’brien 2007).”
Rasi, R., Güveniş, A., & Initiative, T. F. L. D. N. (2025) · Neurodegenerative Diseases · doi:10.1159/000550231 · Cited by 1
“Numerous investigations have focused on interpreting FDG-PET images for early and accurate diagnosis of AD and its stages [13, 14].”
Mahalakshmi, S., & Valarmathi, K. (2025) · Measurement Science Review · doi:10.2478/msr-2025-0043 · Cited by 1
“Other than therapies that slow disease progression, no alternative medication has been identified to stop or cure the disease, despite predictions that nursing and treatment expenses will rise dramatically with the increasing number of patients [6].”
Li, Y., Li, S., Ma, J., Zhao, J., Ning, N., & Sun, J. (2025) · Folia Neuropathologica · doi:10.5114/fn.2025.156508 · Cited by 1
Durgham, B. A., & Alawida, M. (2025) · IEEE/ACS International Conference on Computer Systems and Applications (AICCSA) · doi:10.1109/aiccsa66935.2025.11315300 · Cited by 1
“In addition, the diversity of clinical approaches and the difference in the level of professional qualification among physicians lead to variations in diagnostic efficiency between cases [2].”
Montalbo, F. J. P. (2026) · Applied Soft Computing · doi:10.1016/j.asoc.2026.114624 · Cited by 1
Sorce, D. J., & Michaeli, S. (2026) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2026.108041 · Cited by 1
Yang, Q., Wang, Z., Deng, T., Xia, Y., Shi, F., Feng, J., & Li, C. (2026) · Brain Topography · doi:10.1007/s10548-026-01184-9 · Cited by 1
Kim, N., Lee, M., Shin, J., Kim, J., Pal, A., & Chung, H. U. (2026) · Biomedical Engineering Letters · doi:10.1007/s13534-026-00571-2 · Cited by 1
“FDG-PET likewise faces con - straints in early and differential diagnosis due to its high cost and invasiveness, as well as the fact that hypometa-bolic signals typically appear after neuronal loss and vary across AD subtypes [4].”
Hu, S., Sheng, X., Hu, Y., Ruan, F., Hou, J., Lv, Z., & Valdes-Sosa, P. A. (2026) · IEEE International Conference on Acoustics Speech and Signal Processing · doi:10.1109/icassp55912.2026.11460877 · Cited by 1
Choi, B. K., PARK, J. A., Kim, T. H., Kim, H. C., Ko, I. O., Oh, T. I., Kim, J. W., & Kim, H. J. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261461256 · Cited by 1
Alshammari, A. A. A., & Mani, V. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116335 · Cited by 1
Thakur, D. N., & Goswami, T. (2026) · Life · doi:10.3390/life16091490 · Cited by 1
“These visual findings correspond closely with previous neuroimaging studies that describe ventricular enlargement and cortical surface deformation as hallmark features of AD [4,12].”
Relationships Between Treatment and Clinical Evaluations
Pardi, P. C., & dos Santos, G. A. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-94383-7_9 · Cited by 1
Gender Differences Contribute to Variability of Serum Lipid Biomarkers for Alzheimer'S Disease
Kawakami, J., Piccolo, S., Kauwe, J. S. K., & Graves, S. W. (2022) · Biomarkers in Medicine · doi:10.2217/bmm-2022-0462 · Cited by 1
Díaz, G., Rairán, L. G., Corredor, V., Cruz, A., Useche, D., Wilches, F., & Wilches, L. (2023) · Revista Española de Nutrición Humana y Dietética · doi:10.14306/renhyd.27.1.1826 · Cited by 1
Neurodegenerative Diseases in Geriatric Patients
Russo, C., Senese, R., & Muto, M. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-14877-4_2 · Cited by 1
Neuroprotective Effect of Hydroxysafflor Yellow A on an Alzheimer’s Disease (AD)-Like Mouse Model
Wang, J., Xia, G., Zhang, X., Zhou, G., Ye, Y., Wang, G., & Zhang, Y. (2023) · Biology Bulletin · doi:10.1134/s1062359022603470 · Cited by 1
Wang, L., Zheng, Z., Su, Y., Chen, K., Weidman, D., Wu, T., Lo, S., Lure, F. Y. M., Li, J., Initiative, A. D. N., et al. (2023) · IISE Transactions on Healthcare Systems Engineering · doi:10.1080/24725579.2023.2249487 · Cited by 1
“Neuroimaging data contains rich information about brain alteration associated with AD, which has been demonstrated in various studies [26].”
Understanding Alzheimer’s Disease: A Multidisciplinary Perspective
Akbarzadehmoallemkoalei, M., Yektakasmaei, M. P., Tabar, S. S. S., Zolfaghari, K., Noorikoloori, S., Niktalab, P., Rouzrokh, S., Sheykhzadeh, Z., Sanavi, M. A., Dozdouzan, M. A., et al. (2024) · Integrated science · doi:10.1007/978-3-031-72079-6_14 · Cited by 1
Mehdar, K. M. (2025) · International Journal of Innovative Research and Scientific Studies · doi:10.53894/ijirss.v8i3.6854 · Cited by 1
“These approaches can detect hallmark features of AD, such as amyloid plaques and tau tangles, allowing for early and reliable diagnosis [66, 67].”
Advanced neuroimaging in precision neurology: Tools, trends, and translational impact
Quadri, S. N., Tiwari, S., Siddiqi, B., Fatima, S., Khan, M. A., & Abdin, M. Z. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.08.005 · Cited by 1
Agnollitto, M. I. S. S. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2021.tde-07022022-150515 · Cited by 1
Diagnostic Fluid Biomarkers in Alzheimer’s Disease: Blood and Cerebrospinal FluidPreprint
Park, J. E., Gunasekaran, T. I., Cho, Y. H., Choi, S., Song, M., Cho, S. H., Kim, J., Song, H., Choi, K. Y., Lee, J. J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-763031/v2 · Cited by 1
(2023) · PeerJ Computer Science · doi:10.7287/peerj-cs.1490v0.2/reviews/2 · Cited by 1
(2023) · PeerJ Computer Science · doi:10.7287/peerj-cs.1490v0.1/reviews/3 · Cited by 1
Yu, D., Germann, J., Murtaza, G., Hajdarovic, K. H., Babcock, K. R., Dehkordi, S. K., Jackson, A. C., Delalle, I., Orr, M. E., Zare, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.08.681270 · Cited by 1
Kudo, K. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27760
Női képviselők - Női képviselet? = Women MP's women's representation
Kelemen, I. B. (2009) · CUB Ph.D. Dissertations (Corvinus University of Budapest)
Synthesis of Florbetapir aza-analogues using chemistry of pyridinium N-aminides
Gala, E., Recio, J., Álvarez‐Buílla, J., & Izquierdo, M. L. (2021) · ARKIVOC · doi:10.24820/ark.5550190.p011.676
Principles of Imaging for Epidemiologists
Bello‐Chavolla, O. Y., Vargas‐Vázquez, A., Martínez-Gutiérrez, M. I., Guerra, E. C., Fermín‐Martínez, C. A., & Márquez‐Salinas, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-89601-0_11
Applications of Gold Nanomaterials in Biomedicine
Wu, J., & Wang, Z. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v3i.687
CONCEITUAÇÃO E INVESTIGAÇÃO CLÍNICA DAS DEMÊNCIAS
Rigon, U. D. S., de Oliveira, K. G. F., da Silva, B. L., & Bastos, D. C. C. (2022) · Instituto Produzir eBooks · doi:10.4322/978-65-84941-04-5-001
Demência em Idosos: abordagem interprofissional
(2022) · Instituto Produzir eBooks · doi:10.4322/978-65-84941-04-5
Classification and analysis of Alzheimer’s Disease using Deep Learning methods on MRI and PET
Antony, F., & Anita, H. B. (2022) · International Conference on Multimedia, Signal Processing and Communication Technologies (IMPACT) · doi:10.1109/impact55510.2022.10029052
“This can be a potential diagnostic tool in analysis of the AD initiation in the brain [30].”
BackgroundUse of Design Sprint in PBL Modules– A Longitudinal Case Study Approach
Peiris, T., & Pilapitiya, S. U. (2023) · Global Journal of Computer Science and Technology · doi:10.34257/gjcstcvol23is1pg7
Morison, D. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/kn4up
de Freitas, G. B. L., Fernandes, M. A., de Souza, A. R. C., & da Silva, R. (2023) · doi:10.59290/978-65-6029-034-1
Varnagar, C. R., & Shah, H. B. (2023) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_53_23
7T MRI versus 3T MRI in brain diseases diagnosis
Martinović, J., & Matijaš, T. (2023) · Radiološki vjesnik · doi:10.55378/rv.47.2.4
“This makes 7T an effective diagnostic tool for detecting brain changes caused by Alzheimer’s disease, demonstrating its sensitivity and efficiency [21, 43-45].”
Role of oral microbiota in Alzheimer’s disease: A systematic review of clinical studies
Piao, Q. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/8/20240388
Human Brain Imaging for Cognitive Neuroscience: Data Acquisition and Preprocessing
Shaikh, A. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-1281-0.ch003
Akbarifar, A., Maghsoudpour, A., Mohammadian, F., Mohammadzaheri, M., & Ghaemi, O. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4879419
Rasi, R., & Güveniş, A. (2024) · Research Square · doi:10.21203/rs.3.rs-6252826/v1
Iqbal, R., & Ashraf, Z. (2024) · Asia-Pacific Journal of Oncology · doi:10.32948/ajo.2024.09.09
The Dual Impact of AI in Clinical Trials: Perspective
Yaqub, M., & He, L. (2024) · Journal of Engineering Research and Sciences · doi:10.55708/js0309002
Mahmud, W. M. H. W., Huong, A. K. C., Jumadi, N. A., Izaham, R. M. A. R., & Gan, H. (2024) · Journal of Advanced Research in Applied Sciences and Engineering Technology · doi:10.37934/araset.61.2.4157
“Though available diagnostic techniques such as clinical appraisal, neuropsychological tests, magnetic resonance imaging (MRI) neuroimaging along with positron emission tomography (PET) have some limitations regarding accessibility cost as well as invasiveness [3,4].”
MethodAmankulovas, E., & Lukoševičius, S. (2024) · Health Sciences · doi:10.35988/sm-hs.2024.346
Structural insight of MODAG-005 on 𝛼-Synuclein aggregates as a novel PET tracer
Kim, M. (2024) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10855
Identification of Cognitive Deficits Based on T1-Weighted Magnetic Resonance Imaging
Khazova, M. L., Ushakov, V., Andryushchenko, A. V., Kurmyshev, M. V., Savilov, V., Andreyuk, D., & Kostyuk, G. P. (2024) · Studies in computational intelligence · doi:10.1007/978-3-031-76516-2_16
Crețu, O., Cocu, M., Zelinschi, D. O., & Popescu, E.-R. (2024) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2024.4.03
Genetic Insights and Predictive Models in Alzheimer’s Disease
Zhu, S. (2024) · Transactions on Materials Biotechnology and Life Sciences · doi:10.62051/bsh2zw61
“The identification of these patterns, often referred to as the "disease signature," plays a critical role in distinguishing AD from normal aging and other forms of dementia [15].”
InfluentialO’Neill, W. D., Najera, J., & Datta, M. (2025) · Research Square · doi:10.21203/rs.3.rs-6641557/v1
Early detection of Alzheimer’s disease by using genetic biomarkers
Cheung, M. N. B., Cheung, C. K., Loo, W. T. Y., & Loo, P. C. (2025) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2025.22.3.0619
Early Diagnosis of Alzheimer’s Disease Using Adversarial Techniques
Mamta, & Garla, N. (2025) · Information systems engineering and management · doi:10.1007/978-3-031-91147-7_8
Radiogenomics and Artificial Intelligence in Health and Diseases
Aalam, S. W., Ahanger, A. B., Majeed, T., Ahanger, A. N., Assad, A., Macha, M. A., & Bhat, M. R. (2025) · Springer eBooks · doi:10.1007/978-981-96-8176-1_8
Innovations in imaging technologies for disease modeling and monitoring
Zaidi, S., Singh, P., & Kumar, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33877-9.00013-6
Enhanced Local Feature Extraction for Alzheimer's Diagnosis using Res-VMamba Model
Huang, R. (2025) · International Conference on Artificial Intelligence Technologies and Applications (ICAITA) · doi:10.1109/icaita67588.2025.11137840
“With the advancement of medical imaging technology, structural brain MRI has been widely adopted for auxiliary diagnosis of AD due to its non-invasive and high-resolution characteristics [2-3].”
Duche, A. (2025) · Chapman University Digital Commons (Chapman University) · doi:10.36837/chapman.000705
Segmentation-Guided Development of Visual Classification Criteria for Alzheimer’s DiseasePreprint
Peters, M., Steinbart, D., Hammers, A., Heckemann, R. A., & Initiative, T. A. D. N. (2025) · medRxiv · doi:10.1101/2025.09.29.25336750
Panahi, M., Safaei, A., Ghaderi, F., & Panahi, F. (2025) · Research Square · doi:10.21203/rs.3.rs-7998240/v1
Nathaniel, M., Dauda, W. P., Abraham, P., Ogra, I. O., Jonathan, E. U., Usman, S., Luka, M. I., Glen, E., Daji, M., Ndukwe, J. K., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7915450/v1
A Blood-Based Transcriptomic Algorithm and Scoring System for Alzheimer’s Disease DetectionPreprint
Goyal, P., & Arya, N. (2025) · medRxiv · doi:10.1101/2025.10.21.25338438
FPGA based Implementation of Neuromorphic Neural Networks for Early Detection of Alzheimer’s DiseasePreprint
Sujathakumari, B. A., Usha Rani, M., Shalini, M., & Sneha, N. S. (2025) · Research Square · doi:10.21203/rs.3.rs-7944463/v1
Deshmukh, R. R., Kulkarni, P. H., & Raje, C. S. (2025) · International Conference on Computing Communication Control and automation · doi:10.1109/iccubea65967.2025.11283965
“Over the past several years, researchers have focused a significant amount of emphasis on the molecular imaging of AD [9] [10].”
Daily, K. P., Badr, A., Eltobgy, M. M., Estfanous, S. Z. K., Whitham, O. D., Tan, M. H., Carafice, C., Krause, K., McNamara, A. J., Hamilton, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26678504
Daily, K. P., Badr, A., Eltobgy, M. M., Estfanous, S. Z. K., Whitham, O. D., Tan, M. H., Carafice, C., Krause, K., McNamara, A. J., Hamilton, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26678501
Daily, K. P., Badr, A., Eltobgy, M. M., Estfanous, S. Z. K., Whitham, O. D., Tan, M. H., Carafice, C., Krause, K., McNamara, A. J., Hamilton, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26678507
Establishing the profile of cognitive complaints associated with neurodegenerative dementia
Silva, M. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/ydm8-aa02
Alzheımer Hastalığının Sınıflandırılmasına Yönelik Derin Öğrenme Yöntemleri
al-Hammadi, H. M. A. S. (2023) · DSpace@FSM (FSM Vakif University)
(2023) · UpSpace Institutional Repository (University of Pretoria)
Clinical applications of pupillometry – Audiological research and future prospects
Haipus, F.-M. (2025) · Aaltodoc (Aalto University)
Fereydouni-Forouzandeh, P. (2023) · Corpus Université Laval (Université Laval)
Cervantes, H. A., & Cervantes, H. A. (2023) · UA Campus Repository (The University of Arizona)
Tuna, A. (2023) · eArsiv - Adu (Adnan Menderes University)
Sistema de aprendizaje automático para diagnóstico de alzheimer
Solano Miguel, S. (2025) · EIA University Library (EIA University)
Dezfuli, M. S., Hamdieh, M., Kheradmand, A., Pirnia, B., etedali, H., & Karimi, H. (2025) · Jundishapur Journal of Chronic Disease Care · doi:10.5812/jjcdc-161130
Research Progress on Structural Radiomics of Alzheimer’s Disease Based on Deep Learning
高, 希. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15103015
Ophthalmic imaging and artificial intelligence in early diagnosis of Alzheimer disease
Makarushkina, D. N., Mamedov, V. A., Smagulova, G., Khasanova, A. I., Yunusova, N. F., Dadaev, A. R., Gabbasova, L. K., Sadykova, A. I., Barotova, Z. A., Valeeva, E. R., et al. (2025) · Neurology Bulletin · doi:10.17816/nb690471
Nagamine, T. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v16.i1.112073
Radiogenomic Bipartite Graph Representation Learning for Alzheimer’s Disease Detection
Raj, A., & Mirzaei, G. (2026) · Lecture notes in computer science · doi:10.1007/978-3-032-09513-8_27
IMAGING BIOMARKERS IN DISEASE DIAGNOSIS AND MONITORING
Adeyemo, J. A. (2026) · International Journal of General Medicine · doi:10.34218/ijgmed_04_01_001
López-Ríos, E. E., & Padilla, F. J. A. (2026) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-032-13729-6_27
Plasma Proteomics and Sensitive Imaging Biomarkers of Vascular Brain InjuryPreprint
Yang, Q., Guðmundsdóttir, V., McGrath, E. R., Sargurupremraj, M., Zhu, Y., Maillard, P., CHEN, Z.-Z., Satizábal, C. L., Tahir, U. A., Beiser, A., et al. (2026) · medRxiv · doi:10.64898/2026.01.19.26344369
Enhanced Hybrid Deep Learning Model for Alzheimer Disease Diagnosis
N, B. M. T., Nayana, B. R., & Deepak, S. (2025) · International Conference on Communication, Computer, and Information Technology (IC3IT) · doi:10.1109/ic3it66137.2025.11340957
“Many researchers are investing significant effort in the diagnosis of AD using various data sources and advanced techniques, often combined with cognitive tests and clinical assessments [6].”
Miao, L., Chen, H., Xiang, B., Yuan, Z., Luo, C., & Li, T. (2026) · Applied Soft Computing · doi:10.1016/j.asoc.2026.114716
An integrated CSF-serum biomarker model for predicting clinical progression in Alzheimer’s disease
Wang, X., Tang, Y., Zhang, Q., Xiang, B., Zeng, S., Zhang, Q., Gu, M., & Zou, L. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1728675
Metadata
- Authors
- van Oostveen, W. M., & de Lange, E. C. M.
- Affiliations
- Faculty of Science, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre of Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-02-20
- Volume
- 22
- Issue
- 4
- Pages
- 2110
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7924338
- OpenAlex
- W3131910442
- Cited by
- 297
- References
- 232
- Citations by year
- 2026: 47 · 2025: 84 · 2024: 75 · 2023: 55 · 2022: 24 · 2021: 11
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, neuroimaging biomarkers, early diagnosis, longitudinal disease monitoring, amyloid PET, hippocampal atrophy, hypometabolism, glucose uptake, neurodegeneration, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Longitudinal Studies, Biomarkers, Early Diagnosis, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.